A Study of Imaging in Demyelinating Diseases

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT05805839
Phase
PHASE2
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • C-11 ER176 Radiotracer — DRUG
    Administered at a single time IV prior to the PET imaging. The injected dose of C-11 ER176 will be 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi).
  • C11 Pittsburgh Compound B — DRUG
    Administered at a single time IV prior to the PET imaging. The injected dose of C-11 PiB will be 555 MBq (range 370 - 629 MBq).
  • PET/CT scan — DIAGNOSTIC_TEST
    Imaging of entire brain
  • MRI — DIAGNOSTIC_TEST
    Magnetic Resonance Imaging of the Brain

Study Details

This purpose of this study is research the usefulness of MRI with PET/CT imaging for measuring brain inflammation and its relation to Multiple Sclerosis (MS).

Key Dates

Start date
Jul 10, 2023
Status verified
Aug 2025
Primary completion
May 31, 2028
Completion
May 31, 2028

Study Design

Enrollment
200 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Healthy Control Group
    Subjects without inflammatory-demyelinating diseases of the central nervous system
  • Experimental: Multiple Sclerosis Group
    Subjects with current diagnosis of Multiple Sclerosis or an InflammatoryDemyelinating Disease of the Central Nervous System will have a PET/CT scan with radiotracer drug C-11 PIB \& C-11 ER176

Primary Outcome Measure

Uptake of C-11 Pittsburgh compound-B (PiB) in white matter myelin [ Time Frame: Baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic MinnesotaRochesterMinnesota55905-

Find similar trials in Rochester, MN

By condition
Multiple sclerosis
By specialty
NeurologyBrain disordersAutoimmune disease
By research site
Mayo Clinic Minnesota· Rochester, MN

Related Studies